My Legacy Advisors LLC Has $913,000 Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

My Legacy Advisors LLC cut its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,151 shares of the pharmaceutical company’s stock after selling 76 shares during the quarter. My Legacy Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $913,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Czech National Bank raised its position in shares of Vertex Pharmaceuticals by 6.2% in the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after acquiring an additional 3,260 shares in the last quarter. Whalen Wealth Management Inc. bought a new stake in Vertex Pharmaceuticals in the third quarter worth approximately $662,000. Creative Planning lifted its stake in Vertex Pharmaceuticals by 5.3% in the second quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company’s stock valued at $37,084,000 after buying an additional 3,998 shares during the period. Mizuho Securities USA LLC boosted its holdings in shares of Vertex Pharmaceuticals by 289.0% during the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock worth $35,994,000 after buying an additional 57,497 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Vertex Pharmaceuticals by 19.4% during the 4th quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock worth $137,783,000 after buying an additional 55,739 shares during the period. Institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on VRTX. Morgan Stanley increased their target price on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. UBS Group raised their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Truist Financial cut their price target on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a report on Monday, December 23rd. Stifel Nicolaus boosted their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a report on Monday, December 16th. Finally, Wells Fargo & Company reduced their price target on shares of Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Three analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $490.38.

Vertex Pharmaceuticals Stock Up 1.2 %

NASDAQ:VRTX opened at $422.00 on Friday. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The business has a fifty day simple moving average of $440.94 and a two-hundred day simple moving average of $466.14.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business posted $3.67 EPS. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.